Log In
BCIQ
Print this Print this
 

Epclusa, sofosbuvir/velpatasvir (Sofosbuvir/GS-5816)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionFixed-dose combination of sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and velpatasvir, a pan-genotypic HCV NS5A protein inhibitor
Molecular Target HCV NS5B polymerase ; HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor; HCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1, 2, 4, 5 or 6 infection; Treat chronic HCV genotype 1-6 infection; Treat chronic HCV genotype 2 infection; Treat chronic HCV genotype 2-6 infection; Treat chronic HCV genotype 3 infection; Treat chronic HCV genotypes 1-6 and HIV co-infection; Treat chronic HCV infection; Treat chronic HCV infection in patients with decompensated cirrhosis Child-Pugh class b cirrhosis; Treat hepatitis C virus (HCV)
Regulatory Designation U.S. - Breakthrough Therapy (Treat chronic HCV genotype 1, 2, 4, 5 or 6 infection);
U.S. - Priority Review (Treat chronic HCV genotype 1, 2, 4, 5 or 6 infection)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/07/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today